MediWound (MDWD) Q4 2025 earnings review
Government Shutdown Crushes Q4 Revenue, Trial Milestones Delayed
MediWound ended 2025 on a weak note, with Q4 revenue collapsing 67% YoY to $1.9 million, primarily due to the U.S. government shutdown delaying BARDA contracts. Full-year revenue dropped to $17.0 million from $20.2 million in 2024. While the new NexoBrid manufacturing facility is technically operational, commercial supply remains bottlenecked pending 2026 regulatory approvals. Furthermore, the critical interim assessment for the EscharEx Phase III trial has slipped from 'mid-2026' to 'year-end 2026.' Despite these near-term operational hiccups, the company reaffirmed its aggressive multi-year revenue guidance, targeting $50-55 million by 2028.
🐂 Bull Case
The expanded NexoBrid facility is now operational. Once regulatory approvals (EMA/FDA) are secured in 2026, production capacity will increase sixfold, allowing MediWound to fulfill significant unmet global demand and capitalize on future stockpiling contracts.
The balance sheet remains strong, ending 2025 with $53.6 million in cash and equivalents. This provides sufficient runway to fund the cash-intensive EscharEx VALUE Phase III trial through its completion.
🐻 Bear Case
The interim sample size assessment for the Phase III VALUE trial, previously guided for mid-2026, is now expected by year-end 2026. This delay pushes back the ultimate commercialization timeline of the company's primary value driver.
The Q4 revenue collapse exposes vulnerability to government bureaucracy. With BARDA and DoD funding paused or delayed due to a U.S. government shutdown, near-term top-line stability is highly questionable.
⚖️ Verdict: 🔴
Bearish. Short-term execution is suffering. Revenue missed expectations due to political factors outside management's control, product sales to Vericel dropped for the year, and the pivotal EscharEx trial has been delayed. The long-term guidance remains bullish, but 2026 must be a flawless year of regulatory approvals to regain credibility.
Key Themes
EscharEx Phase III Timeline Quietly Pushed Back
Throughout 2025, management repeatedly guided that the interim sample size assessment for the 216-patient EscharEx VALUE trial would occur in 'mid-2026' after 65% of patients completed treatment. In the Q4 release, this milestone has been quietly delayed to 'year-end 2026.' This represents a Decelerating timeline for MediWound's most critical R&D asset.
Revenue Concentration and Government Dependency
Total revenue in Q4 Reversing to $1.9M from $5.8M a year ago highlights severe concentration risk. Management attributed the decline primarily to the U.S. government shutdown, which delayed budget approvals and the initiation of new BARDA/DoD contractual agreements. This indicates that underlying commercial sales of NexoBrid are currently insufficient to smooth out lumpiness in government funding.
NexoBrid Capacity Expansion Ready, Awaiting Regulatory Green Light
The structural bottleneck for NexoBrid sales has been manufacturing capacity. The new facility, built to increase capacity sixfold, is now officially operational. However, commercial supply from this facility remains capped pending EMA and FDA regulatory approvals expected in 2026. Once cleared, this will trigger an Accelerating revenue profile.
EscharEx Ecosystem Validation Expanding
B. Braun has joined the EscharEx clinical development program via a research collaboration agreement. This adds to an extensive list of top-tier wound care partners, including Coloplast/Kerecis, Convatec, Essity, Mölnlycke, Solventum, and MIMEDX, validating industry interest in the technology's ability to prepare wound beds.
Other KPIs
Decelerating. The operating loss widened significantly from $6.1 million in 24Q4, driven by a simultaneous collapse in top-line revenue ($1.9M vs $5.8M) and a 50% YoY surge in R&D expenses ($4.5M vs $3.0M) related to the EscharEx trial.
Stable. Up from $43.6 million at the end of 2024, fortified by a $30 million direct offering in Q3 2025 and $3.5 million from warrant exercises. The company burned $21.4 million in operating activities during the year, suggesting roughly two years of runway without additional funding.
Accelerating. Gross margin improved notably from 13.0% in 2024 to 19.2% in 2025, largely due to a favorable change in revenue mix throughout the year, even factoring in the Q4 revenue miss.
Guidance
Accelerating. The midpoint of $25 million implies a 47% YoY growth rate compared to the depressed 2025 base of $17.0 million. This guidance explicitly assumes continued support from BARDA and the DoD, meaning a resolution to recent government budget delays is required to hit this target.
Accelerating. Reaffirmed guidance implying a ~34% YoY growth rate at the midpoint ($33.5M). This relies on the new NexoBrid facility receiving full regulatory clearance in 2026 to support massive capacity expansion and international sales growth.
Accelerating. This ambitious target implies ~57% YoY growth from 2027. Crucially, the company noted that this outlook includes a 'potential initial contribution from EscharEx, subject to regulatory approval,' indicating they expect an EscharEx launch by 2028.
Key Questions
EscharEx Trial Delay
The interim assessment for the Phase III VALUE trial has shifted from 'mid-2026' to 'year-end 2026.' What specifically caused this delay—was it the EU site activation hurdles mentioned in Q3, slower patient enrollment, or something else?
BARDA Contract Status
Given the U.S. government shutdown severely impacted Q4 revenue, what is the current visibility into the resumption of BARDA/DoD funding, and has the multi-year BARDA RFP been formally awarded yet?
NexoBrid Regulatory Timelines
The new facility is operational but pending regulatory approvals in 2026. Can you provide a more precise timeline for the expected EMA and FDA inspections to give investors confidence in the 2026 revenue guidance?